Deletion 5q in myelodysplastic syndrome: A paradigm for the study of hemizygous deletions in cancer

Leukemia

Volumn 23, Issue 7, 2009, Pages 1252-1256

  Ebert, B L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD131 ANTIGEN; EARLY GROWTH RESPONSE FACTOR 1; INTERLEUKIN 13; INTERLEUKIN 17BETA; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; LENALIDOMIDE; NUCLEOPHOSMIN; OSTEONECTIN; PROTEIN CDC25C; PROTEIN CTNNA1; PROTEIN FGR1; PROTEIN PP2A; PROTEIN RPS14; PROTEIN RPS19; RIBOSOME PROTEIN; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR RUNX1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

5Q- SYNDROME; ALLELE; APOPTOSIS; BLACKFAN DIAMOND ANEMIA; CARCINOGENESIS; CELL PROLIFERATION; CHROMOSOME 5Q; CHROMOSOME DELETION; CYTOGENETICS; DEACETYLATION; DRUG MECHANISM; EPIGENETICS; ERYTHROID CELL; GENE LOCUS; GENETIC ENGINEERING; GENETIC STABILITY; HEMATOCRIT; HEMATOPOIETIC STEM CELL; HEMIZYGOSITY; HUMAN; IN SITU HYBRIDIZATION; LYMPHOMA; METHYLATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; THROMBOCYTOPENIA;

EID: 67650859652     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.53     Document Type: Review

References (59)

1. Knudson Jr AG. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68: 820-823.
2. Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med 2008; 359: 2143-2153.
3. Fodde R, Smits R. Cancer biology. A matter of dosage. Science 2002; 298: 761-763.
4. Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci USA 2001; 98: 9742-9747.
5. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-498.
6. Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G et al A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006; 124: 1283-1298.
7. Rubinson D, Dillon C, Kwiatkowski A, Sievers C, Yang L, Kopinja J et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genetics 2003; 33: 401-405.
8. Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 1974; 251: 437-438.
9. Boultwood J, Lewis S, Wainscoat JS. The 5q- syndrome. Blood 1994; 84: 3253-3260.
10. Giagounidis AA, Germing U, Wainscoat JS, Boultwood J, Aul C. The 5q- syndrome. Hematology 2004; 9: 271-277.
11. Lewis S, Oscier D, Boultwood J, Ross F, Fitchett M, Rack K et al. Hematological features of patients with myelodysplastic syndromes associated with a chromosome 5q deletion. Am J Hematol 1995; 49 194-200.
12. Mahmood T, Robinson WA, Hamstra RD, Wallner SF. Macrocytic anemia, thrombocytosis and nonlobulated megakaryocytes: The 5q-syndrome, a distinct entity. Am J Med 1979; 66: 946-950.
13. Mathew P, Tefferi A, Dewald GW, Goldberg SL, Su J, Hoagland HC et al The 5q- syndrome: A single-institution study of 43 consecutive patients. Blood 1993; 81: 1040-1045.
14. Nimer SD. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. J Clin Oncol 2006; 24 2576-2582.
15. Vardiman J. Myelodysplastic syndrome with isolated del(5q) chromosome abnormality. Blood 2003; 101: 3346.
16. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
17. Holtan SG, Santana-Davila R, Dewald GW, Khetterling RP, Knudson RA, Hoyer JD et al. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: Clinicopathologic correlations and new insights from the pre-lenalidomide era. Am J Hematol 2008; 83: 708-713.
18. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
19. Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients. Blood 2007; 110: 4385-4395.
20. Le Beau MM, Westbrook CA, Diaz MO, Larson RA, Rowley JD, Gasson JC et al. Evidence for the involvement of GM-CSF and FMS in the deletion (5q) in myeloid disorders. Science 1986; 231: 984-987.
21. Willman CL, Sever CE, Pallavicini MG, Harada H, Tanaka N, Slovak ML et al. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 1993; 259: 968-971.
22. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med 1999; 340: 1649-1660.
23. Boultwood J, Fidler C, Lewis S, Kelly S, Sheridan H, Littlewood TJ et al. Molecular mapping of uncharacteristically small 5q deletions in two patients with the 5q- syndrome: Delineation of the critical region on 5q and identification of a 5q- breakpoint. Genomics 1994; 19 425-432.
24. Boultwood J, Fidler C, Strickson AJ, Watkins F, Gama S, Kearney L et al. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood 2002; 99: 4638-4641.
25. Jaju RJ, Boultwood J, Oliver FJ, Kostrzewa M, Fidler C, Parker N et al. Molecular cytogenetic delineation of the critical deleted region in the 5q- syndrome. Genes Chromosomes Cancer 1998; 22: 251-256.
26. Horrigan SK, Arbieva ZH, Xie HY, Kravarusic J, Fulton NC, Naik H et al. Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31. Blood 2000; 95: 2372-2377.
27. Horrigan SK, Westbrook CA, Kim AH, Banerjee M, Stock W, Larson RA. Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval. Blood 1996; 88: 2665-2670.
28. Zhao N, Stoffel A, Wang PW, Eisenbart JD, Espinosa III R, Larson RA et al. Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci USA 1997; 94 6948-6953.
29. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-1214.
30. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77: 307-316.
31. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446: 758-764.
32. Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D et al Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999; 23: 166-175.
33. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008; 451: 335-339.
34. Boultwood J, Pellagatti A, Cattan H, Lawrie CH, Giagounidis A, Malcovati L et al. Gene expression profiling of CD34+ cells in patients with the 5q- syndrome. Br J Haematol 2007; 139: 578-589.
35. Valencia A, Cervera J, Such E, Sanz MA, Sanz GF. Lack of RPS14 promoter aberrant methylation supports the haploinsufficiency model for the 5q- syndrome. Blood 2008; 112: 918.
36. Choesmel V, Fribourg S, Aguissa-Toure AH, Pinaud N, Legrand P, Gazda HT et al. Mutation of ribosomal protein RPS24 in Diamond-Blackfan anemia results in a ribosome biogenesis disorder. Hum Mol Genet 2008; 17: 1253-1263.
37. Cmejla R, Cmejlova J, Handrkova H, Petrak J, Pospisilova D. Ribosomal protein S17 gene (RPS17) is mutated in Diamond-Blackfan anemia. Hum Mutat 2007; 28: 1178-1182.
38. Draptchinskaia N, Gustavsson P, Andersson B, Pettersson M, Willig TN, Dianzani I et al. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat Genet 1999; 21: 169-175.
39. Gazda HT, Grabowska A, Merida-Long LB, Latawiec E, Schneider HE, Lipton JM et al. Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia. Am J Hum Genet 2006; 79: 1110-1118.
40. Choesmel V, Bacqueville D, Rouquette J, Noaillac-Depeyre J, Fribourg S, Cretien A et al. Impaired ribosome biogenesis in Diamond-Blackfan anemia. Blood 2007; 109: 1275-1283.
41. Flygare J, Aspesi A, Bailey JC, Miyake K, Caffrey JM, Karlsson S et al. Human RPS19, the gene mutated in Diamond-Blackfan anemia, encodes a ribosomal protein required for the maturation of 40S ribosomal subunits. Blood 2007; 109: 980-986.
42. Farrar JE, Nater M, Caywood E, McDevitt MA, Kowalski J, Takemoto CM et al. Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond-Blackfan anemia. Blood 2008; 112: 1582-1592.
43. Liu JM, Ellis SR. Ribosomes and marrow failure: Coincidental association or molecular paradigm? Blood 2006; 107: 4583-4588.
44. Danilova N, Sakamoto KM, Lin S. Ribosomal protein S19 deficiency in zebrafish leads to developmental abnormalities and defective erythropoiesis through activation of p53 protein family. Blood 2008; 30: 30.
45. McGowan KA, Li JZ, Park CY, Beaudry V, Tabor HK, Sabnis AJ et al. Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. Nat Genet 2008; 40: 963-970.
46. Uechi T, Nakajima Y, Chakraborty A, Torihara H, Higa S, Kenmochi N. Deficiency of ribosomal protein S19 during early embryogenesis leads to reduction of erythrocytes in a zebrafish model of Diamond-Blackfan anemia. Hum Mol Genet 2008; 17: 3204-3211.
47. Amsterdam A, Sadler KC, Lai K, Farrington S, Bronson RT, Lees JA et al. Many ribosomal protein genes are cancer genes in zebrafish. PLoS Biol 2004; 2: E139.
48. Wei S, Rocha K, Williams A, Chen X, Burnette PK, Djeu JY et al. Gene dosage of the cell cycle regulatory phosphatases Cdc25C and PP2A determines sensitivity ot lenalidomide in del(5q) MDS. Blood 2007; 110, (abstract 118).
49. Liu TX, Becker MW, Jelinek J, Wu WS, Deng M, Mikhalkevich N et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med 2007; 13: 78-83.
50. Ebert BL, Galili N, Tamayo P, Bosco J, Mak R, Pretz J et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 2008; 5: E35.
51. Pellagatti A, Jadersten M, Forsblom AM, Cattan H, Christensson B, Emanuelsson EK et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci USA 2007; 104: 11406-11411.
52. Lehmann S, O0Kelly J, Raynaud S, Funk SE, Sage EH, Koeffler HP. Common deleted genes in the 5q- syndrome: Thrombocytopenia and reduced erythroid colony formation in SPARC null mice. Leukemia 2007; 21: 1931-1936.
53. Fidler C, Strickson A, Boultwood J, Waincoat JS. Mutation analysis of the SPARC gene in the 5q-syndrome. Am J Hematol 2000; 64: 324.
54. Joslin JM, Fernald AA, Tennant TR, Davis EM, Kogan SC, Anastasi J et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood 2007; 110 719-726.
55. Min IM, Pietramaggiori G, Kim FS, Passegue E, Stevenson KE, Wagers AJ. The transcription factor EGR1 controls both the proliferation and localization of hematopoietic stem cells. Cell Stem Cell 2008; 2: 380-391.
56. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254-266.
57. Grisendi S, Bernardi R, Rossi M, Cheng K, Khandker L, Manova K et al Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005; 437: 147-153.
58. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer 2006; 6: 493-505.
59. Sportoletti P, Grisendi S, Majid SM, Cheng K, Clohessy JG, Viale A et al. Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood 2008; 111: 3859-3862.